Skip to main content
SpringerLink
Log in

Modern methods of drug discovery: An introduction

  • Chapter
Modern Methods of Drug Discovery

Part of the book series: EXS ((EXS,volume 93))

Abstract

The pharmaceutical industry is continuing to attempt double-digit growth rates driven by high market capitalization. Standard responses to this challenge have only provided limited impact. Besides scaling-up businesses through mergers or selective acquisitions of platform technologies or drug candidates, an increase of Research and Development (R&D) productivity still represents a sure approach to address this challenge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. PhRMA (2000) Based on data from PhRMA Annual Survey and Standard & Poor’s Compustat, a division of McGraw-Hill

    Google Scholar 

  2. PhRMA Annual Survey (2000)

    Google Scholar 

  3. Report issued by Bain & Company Germany Inc. (2001)

    Google Scholar 

  4. Boston Consulting Group. A revolution in R&D. (2001)

    Google Scholar 

  5. DiMasi JA (2001) Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 69: 297–307

    Article  PubMed  CAS  Google Scholar 

  6. Report issued by the Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA (1998)

    Google Scholar 

  7. Peck CC (1997) Drug development: improving the process. Food Drug Law J 52: 163–167

    PubMed  CAS  Google Scholar 

  8. Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960–1964

    Article  PubMed  CAS  Google Scholar 

  9. Ward SJ (2001) Impact of genomics in drug discovery. Biotechniques 31: 626–630

    PubMed  CAS  Google Scholar 

  10. Cunningham MT (2000) Genomics and proteomics: the new millennium of drug discovery and devel-op. ment J Pharmacol Toxicol Methods 44: 291–300

    Article  PubMed  CAS  Google Scholar 

  11. Dongre AR, Opiteck G, Cosand WL et al (2001) Proteomics in the post-genome age. Biopolymers 60: 206–211

    Article  PubMed  CAS  Google Scholar 

  12. Augen J (2002) The evolving role of information technology in the drug discovery process. Drug Discov Today 7: 315–323

    Article  PubMed  CAS  Google Scholar 

  13. Davies EK, Richards WG (2002) The potential of Internet computing for drug discovery. Drug Discov Today 7: S99–S103

    Article  PubMed  CAS  Google Scholar 

  14. Lander ES, Linton LM, Birren B et al (2001) Initial sequencing and analysis of the human genome. Nature 409: 860–921

    Article  PubMed  CAS  Google Scholar 

  15. Venter JC, Adams MD, Myers EW et al (2001) The sequence of the human genome. Science 291: 1304–1351

    Article  PubMed  CAS  Google Scholar 

  16. National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD 20894, http://www.ncbi.nlm.nih.gov. (2002)

  17. Searls DB (2000) Using bioinformatics in gene and drug discovery. Drug Discov Today 5: 135–143

    Article  PubMed  CAS  Google Scholar 

  18. Hogenesch JB, Ching KA, Batalov S et al (2001) A comparison of the Celera and Ensembl predicted gene sets reveals little overlap in novel genes. Cell 106: 413–415

    Article  PubMed  CAS  Google Scholar 

  19. Wright FA, Lemon WJ, Zhao WD et al (2001) A draft annotation and overview of the human genome. Genome Biol 2: RESEARCH00251–002518

    Google Scholar 

  20. Duckworth DM, Sanseau P (2002) In silico identification of novel therapeutic targets. Drug Discov Today 7: S64–S69

    Article  PubMed  CAS  Google Scholar 

  21. Sanseau P (2001) Impact of human genome sequencing for in silico target discovery. Drug Discov Today 6: 316–323

    Article  PubMed  CAS  Google Scholar 

  22. Tang CM, Moxon ER (2001) The impact of microbial genomics on antimicrobial drug development. Annu Rev Genomics Hum Genet 2: 259–269

    Article  PubMed  CAS  Google Scholar 

  23. Herrmann R, Reiner B (1998) Mycoplasma pneumoniae and Mycoplasma genitalium: a comparison of two closely related bacterial species. Curr Opin Microbiol 1: 572–579

    Article  PubMed  CAS  Google Scholar 

  24. Noordewier MO, Warren PV (2001) Gene expression microarrays and the integration of biological knowledge. Trends Biotechnol 19: 412–415

    Article  PubMed  CAS  Google Scholar 

  25. Kennedy GC (2000) The impact of genomics on therapeutic drug development. EXS 89: 1–10

    PubMed  CAS  Google Scholar 

  26. Gygi SP, Rochon Y, Franza BR et al (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720–1730

    PubMed  CAS  Google Scholar 

  27. Loo JA, DeJohn DE, Du P et al (1999) Application of mass spectrometry for target identification and characterization. Med Res Rev 19: 307–319

    Article  PubMed  CAS  Google Scholar 

  28. Abuin A, Holt KH, Platt KA et al (2002) Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 20: 36–42

    Article  PubMed  CAS  Google Scholar 

  29. Tornell J, Snaith M (2002) Transgenic systems in drug discovery: from target identification to humanized mice. Drug Discov Today 7: 461–470

    Article  PubMed  CAS  Google Scholar 

  30. Sanseau P (2001) Transgenic gene knockouts: a functional platform for the industry. Drug Discov Today 6: 770–771

    Article  PubMed  Google Scholar 

  31. Dean NM (2001) Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr Opin Biotechnol 12: 622–625

    Article  PubMed  CAS  Google Scholar 

  32. Tse E, Lobato MN, Forster A et al (2002) Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J Mol Biol 317: 85–94

    Article  PubMed  CAS  Google Scholar 

  33. Burley SK (2000) An overview of structural genomics. Nat Struct Biol 7 Suppl: 932–934

    Article  PubMed  CAS  Google Scholar 

  34. Service RF (2000) Structural genomics offers high-speed look at proteins. Science 287: 1954–1956

    Article  PubMed  CAS  Google Scholar 

  35. Dean PM, Zanders ED (2002) The use of chemical design tools to transform proteomics data into drug candidates. Biotechniques Suppl: 28–33

    Google Scholar 

  36. Willson TM, Jones SA, Moore JT et al (2001) Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med Res Rev 21: 513–522

    Article  PubMed  CAS  Google Scholar 

  37. Lenz GR, Nash HM, Jindal S (2000) Chemical ligands, genomics and drug discovery. Drug Discov Today 5: 145–156

    Article  PubMed  CAS  Google Scholar 

  38. Hertzberg RP, Pope At (2000) High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 4: 445–451

    Article  PubMed  CAS  Google Scholar 

  39. Wolcke J, Ullmann D (2001) Miniaturized HTS technologies — uHTS. Drug Discov Today 6: 637–646

    Article  PubMed  Google Scholar 

  40. Wess G, Urmann M, Sickenberger B (2001) Medicinal Chemistry: Challenges and Opportunities. Angew Chem Int Ed Engl 40: 3341–3350

    Article  PubMed  CAS  Google Scholar 

  41. Drews J (2000) Drug discovery today — and tomorrow. Drug Discov Today 5: 2–4

    Article  PubMed  Google Scholar 

  42. Harvey AL (1999) Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol Sci 20: 196–198

    CAS  Google Scholar 

  43. Sundberg SA (2000) High-throughput and ultra-high-throughput screening: solution-and cell-based approaches. Curr Opin Biotechnol 11: 47–53

    Article  PubMed  CAS  Google Scholar 

  44. Silverman L, Campbell R, Broach JR (1998) New assay technologies for high-throughput screening. Curr Opin Chem Biol 2: 397–403

    Article  PubMed  CAS  Google Scholar 

  45. Schneider G, Böhm HJ (2002) Virtual screening and fast automated docking methods. Drug Discov Today 7: 64–70

    PubMed  CAS  Google Scholar 

  46. Toledo-Sherman LM, Chen D (2002) High-throughput virtual screening for drug discovery in parallel. Curr Opin Drug Discov Devel 5: 414–421

    PubMed  CAS  Google Scholar 

  47. Shuker SB, Hajduk PJ, Meadows RP et al (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274: 1531–1534

    Article  PubMed  CAS  Google Scholar 

  48. Brennan MB (2000) Drug Discovery: filtering out failures early in the game. Chemical & Engineering News 78: 63–73

    Article  Google Scholar 

  49. Bachmann KA, Ghosh R (2001) The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2: 299–314

    Article  PubMed  CAS  Google Scholar 

  50. Vogel HG (2001) Drug Discovery and Evaluation. Pharmacological Assays. Springer-Verlag, Berlin Heidelberg

    Google Scholar 

  51. Beresford AP, Selick HE, Tarbit MH (2002) The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today 7: 109–116

    Article  PubMed  CAS  Google Scholar 

  52. Butina D, Segall MD, Frankcombe K (2002) Predicting ADME properties in silico: methods and models. Drug Discov Today 7: S83–S88

    Article  PubMed  CAS  Google Scholar 

  53. Roses AD (2001) Pharmacogenetics. Hum Mol Genet 10: 2261–2267

    Article  PubMed  CAS  Google Scholar 

  54. Roses AD (2000) Pharmacogenetics and the practice of medicine. Nature 405: 857–865

    Article  PubMed  CAS  Google Scholar 

  55. Vesell ES (2000) Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 40: 930–938

    Article  PubMed  CAS  Google Scholar 

  56. McCarthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18: 505–508

    Article  PubMed  CAS  Google Scholar 

  57. Tomita M (2001) Whole-cell simulation: a grand challenge of the 21st century. Trends Biotechnol 19: 205–210

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Curacyte AG, Gollierstr. 70, München, D-80339, Germany

    Helmut Giersiefen

  2. Institut für Molekulare Biotechnologie e.V., Beutenbergstr. 11, Jena, D-07745, Germany

    Rolf Hilgenfeld

  3. EnTec GmbH, Adolf-Reichwein-Str. 20, Jena, D-07745, Germany

    Alexander Hillisch

Authors
  1. Helmut Giersiefen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rolf Hilgenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Hillisch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Structural Bioinformatics and Drug Design, EnTec GmbH, Adolf-Reichwein-Straße 20, Jena, D-07745, Germany

    Alexander Hillisch

  2. Institut für Molekulare Biotechnologie e.V., Abt. Strukturbiologie-Kristallographie, Beutenbergstraße 11, Jena, D-07745, Germany

    Rolf Hilgenfeld

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Basel AG

About this chapter

Cite this chapter

Giersiefen, H., Hilgenfeld, R., Hillisch, A. (2003). Modern methods of drug discovery: An introduction. In: Hillisch, A., Hilgenfeld, R. (eds) Modern Methods of Drug Discovery. EXS, vol 93. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7997-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7997-2_1

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9397-8

  • Online ISBN: 978-3-0348-7997-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation